Scientists at ARVO have presented a poster demonstrating the reduction of central corneal thickness in glaucomatous eyes treated with prostaglandins or with a combination of beta blockers, prostaglandins and carbonic anhydrase inhibitors.
In a trial evaluating diagnostic and prognostic validity of morphometric, sensory and hemodynamic diagnostic procedures in glaucomatous eyes, researchers followed 405 eyes with ocular hypertension, suspected glaucoma, perimetric glaucoma or no glaucoma with standard automated perimetry, 24-hour IOP profile, optic disc photography and optical coherence pachymetry (Heidelberg Engineering).
In Healio Ophthalmology, Professor Wolfgang A. Schrems reported that, “the prostaglandins resulted in reduction in central corneal thickness (CCT) over time, so it is crucial to do some CCT measurements. Carbonic anhydrase inhibitors (CAI) resulted in an increase in CCT, and this combination therapy (beta blockers, prostaglandins and CAI) resulted in the most pronounced decrease of CCT, but the effects are not dramatic.”
Eyes treated with prostaglandins resulted in a decrease in CCT of –4.9 µm a year, while eyes treated with only CAI increased by +6.5 µm a year.
the prostaglandins resulted in reduction in central corneal thickness (CCT) over time
No statistically significant change was seen either in untreated eyes or in eyes treated with beta blocker alone, beta blocker with CAI or prostaglandin with CAI.
“Follow-up IOP measurements may be underestimated for eyes treated with beta blockers, prostaglandins and CAI and overestimated for those treated with CAI if CCT is not measured on a regular basis,” he reported.